

FIRST CALL


DAILY REPORT

MARKETS

Change in %

	08-Oct-25	1D	1M	1Y
Nifty 50	25,046	-0.2	0.7	0.3
Nifty 200	13,972	-0.4	0.8	-1.6
Nifty 500	23,109	-0.4	0.7	-2.1

INDIA STOCK PERFORMANCE



GLOBAL

	08-Oct-25	1D	1M	1Y
Dow	46,775	0.4	2.8	11.2
China	3,883	0.5	2.0	19.1
EM Index	1,375	0.2	7.3	18.9

UPCOMING EVENTS CALENDER

Date	Event
09-Oct-25	TCS - Financial Results
09-Oct-25	Tata Elxsi - Board Meeting
10-Oct-25	IndiGrid Infra. - Fund Raising
10-Oct-25	Elecon Engineering - Financia Results

MACRO

Change in %

	08-Oct-25	1D	1M	1Y
Fx (INR/USD)	88.8	0.0	-0.6	-5.4
!0-yr G-sec	6.5	-0.1	0.6	-4.5
Oil (USD)	66.3	1.3	0.5	-14.1

PRESTIGE - Company Update - Q2FY26: Stellar show

Prestige Estates (PEPL) clocked pre-sales of ~INR60.2bn (up 50% YoY) in Q2FY26 aided by launch of four projects spanning ~3.9msf (down 52% YoY) with GDV of ~INR39.7bn. H1FY26 pre-sales at INR181.4bn (up 2.6x YoY) have surpassed FY25 pre-sales. Q2 and H1FY26 collections jumped 54% YoY each. The company delivered ~2.5msf projects during the quarter. Occupancy in the office/retail portfolio stood at a healthy 93.4%/99%. Consumption in malls jumped 9% YoY.

Consumer Sector – Q2FY26 Results Preview – Insights from Business Updates and updated preview

Top picks: Staples: Bikaji Foods, Britannia, Nestle, Tata Consumer and HUL; in Discretionary, we also like United Spirits and Asian Paints.

Formal Business Updates: Godrej Consumer, Dabur and Marico in line with our published preview (dated September 29). AWL Agri positively surprised on revenue growth of 24% YoY and volume growth of 5% YoY. Based on Business Updates, minor tweaks have been made to our earlier Q2FY26 preview in this report.

Healthcare - Sector Update - Selective resilience amid soft season

We reckon the healthcare sector's Q2FY26E EBITDA shall expand ~17% YoY driven by ~18% growth in hospitals and ~12% in diagnostics. The growth is lower than Q1 owing to low seasonal incidences, delayed elective surgeries due to extended monsoons and festivals and high base. Highlights: i) Diagnostics shall report 11–12% organic growth, margin resilient. ii) Hospitals soft, especially APHS, leading to lower occupancy (~560bp lower than Q2FY25). iii) Apollo Pharmacy's growth to sustain at ~17% YoY, while Medplus's growth to improve at ~7%.

Engineering and capital goods - Sector Update - HV T&D to power ahead

We reckon Nuvama Industrials coverage shall post base OI growth of ~21.7% YoY (ex-BHEL and Siemens) and revenue growth of ~14.5% YoY in Q2FY26E with the consolidated order book rising to ~INR10.7tn on the back of strong awarding in Thermal Gen, Renewables and Power T&D, supported by data centres, EVs and semiconductors.

Insider & Bulk Deal

India Derivative Insights

Sectoral Movements

%Change

Ticker	8-Oct-25	1 D	1 M	3 M	1 Y
NIFTY INDEX	25,046	-0.2	0.7	-1.7	0.3
BANKEX Index	63,051	-0.4	4.1	-1.4	8.7
CNXIT Index	35,232	1.5	-0.1	-8.9	-17.3
BSEHEAL INDEX	43,883	-0.4	-1.2	-1.3	-1.8
BSEOIL Index	27,284	-0.7	5.6	-3.1	-8.9
BSEPOW Index	6,706	-1.5	2.4	-3.2	-20.1
BSEAUTO Index	59,242	-1.3	-2.3	10.6	-0.9
BSEMET Index	33,560	-0.2	3.8	7.6	1.4
BSEREA Index	6,798	-1.9	0.1	-9.6	-17.3
BSEFMC Index	20,072	-0.4	-3.4	-2.5	-11.6
BSECAP Index	68,690	-1.2	2.4	-4.8	-3.6

PRESTIGE ESTATES

COMPANY UPDATE

KEY DATA

Rating	BUY
Sector relative	Neutral
Price (INR)	1,514
12 month price target (INR)	1,966
52 Week High/Low	1,910/1,048
Market cap (INR bn/USD bn)	652/7.3
Free float (%)	34.5
Avg. daily value traded (INR mn)	1,230.4

SHAREHOLDING PATTERN


	Jun-25	Mar-25	Dec-24
Promoter	60.94%	60.94%	60.94%
FII	17.08%	19.3%	19.12%
DII	19.23%	16.73%	16.75%
Pledge	0%	0%	0%

FINANCIALS

(INR mn)

Year to March	FY25A	FY26E	FY27E	FY28E
Revenue	73,494	1,19,990	1,87,247	2,34,521
EBITDA	25,588	40,047	58,521	80,583
Adjusted profit	4,675	10,552	21,492	5,712
Diluted EPS (INR)	10.9	24.5	49.9	13.3
EPS growth (%)	(68.3)	125.7	103.7	(73.4)
RoAE (%)	3.5	6.6	12.2	3.0
P/E (x)	139.5	61.8	30.3	114.1
EV/EBITDA (x)	28.7	18.9	13.3	9.9
Dividend yield (%)	0.1	0.1	0.1	0.1

PRICE PERFORMANCE



Q2FY26: Stellar showing

Prestige Estates (PEPL) clocked pre-sales of ~INR60.2bn (up 50% YoY) in Q2FY26 aided by launch of four projects spanning ~3.9msf (down 52% YoY) with GDV of ~INR39.7bn. H1FY26 pre-sales at INR181.4bn (up 2.6x YoY) have surpassed FY25 pre-sales. Q2 and H1FY26 collections jumped 54% YoY each. The company delivered ~2.5msf projects during the quarter. Occupancy in the office/retail portfolio stood at a healthy 93.4%/99%. Consumption in malls jumped 9% YoY.

As highlighted in our report [Making sense of housing cycle](#), Bengaluru can still deliver volume growth even as concerns remain around other markets. Maintain 'BUY' with a revised TP of INR1,966 (earlier INR2,009) as we roll forward the valuation to Q2FY28E.

Pre-sales surge YoY in Q2FY26

PEPL's pre-sales value surged 50% YoY (down 50% QoQ as Q1FY26 witnessed best-ever quarterly pre-sales) to INR60.2bn in Q2FY26. The company launched a new phase in the Indirapuram project (NCR) and three plotted development projects in Q2FY26 with GDV of ~INR39.7bn. Sales volumes at ~4.4msf increased 47% YoY (down 54% QoQ). Sales during the quarter were well diversified across Bengaluru (40% share), Mumbai (22%), the NCR (18%), Hyderabad (11%), Chennai (7%), etc.

H1FY26 pre-sales stood at ~INR181.4bn (up 2.6x YoY)—its highest-ever H1 pre-sales across ~14msf (up 2.4x YoY). Launches in H1FY26 have surged 1.9x YoY to 18.8msf with GDV of ~INR176bn. The company has been able to sell ~60% of inventory in *Prestige Nautilus* project in Mumbai for ~INR44bn and has garnered pre-sales/collections of INR83/15bn in its maiden project in the NCR within a few months of launch.

Collections rise but completions fall YoY

The company delivered two projects spanning ~2.5msf in Bengaluru during the quarter (down 17% YoY/54% QoQ). H1FY26 completions stand at ~8msf against ~3msf in FY25. Collections during the quarter came in at INR42.1bn (up 54% YoY but down 7% QoQ). H1FY26 collections at ~INR87.3bn were up 54% YoY—its highest-ever H1 collections.

Price realisation increases YoY in Q2FY26

Average realisation for apartments, villas and commercial properties rose 8% YoY to INR14,906/sft in Q2FY26 while plotted sales logged average realisation of INR9,510/sft (up 43% YoY).

Annuity business performing well

Gross leasing in the office segment stood at 2.3msf in Q2FY26 and ~3.5msf in H1FY26 (~4.1msf in FY25). The office portfolio's occupancy stood at ~93.4% with exit rental at INR8.2bn. Consumption in the malls in Q2FY26 stood at ~INR6.2bn and ~INR12.1bn in H1FY26 (INR22.6bn in FY25). The retail portfolio enjoys occupancy of 99% with exit rentals of ~INR2.7bn. Footfalls reached ~4.8mn during the quarter.

October 2025

Consumer Sector

GST transition plays spoilsport

Insights from Business Updates and updated preview

Content

- ✓ Q2FY26 Preview Summary; Top picks—GST transition pain in short term; recovery November onwards
- ✓ Q2FY26 business updates – Staples and discretionary
- ✓ Top-tier, mid-tier and laggards in Q2
- ✓ Palm oil could be slight worry for food companies in Q3FY26
- ✓ Nepal political uncertainty—Slight overhang
- ✓ Impact of unseasonal rains on summer portfolio
- ✓ Winter could be harsh in H2 helping demand in few segments
- ✓ Delhi government likely to reform liquor sector—potentially positive for Alco Bev sector
- ✓ Changes in key raw material prices
- ✓ Volumes, revenue and EBITDA comparison YoY
- ✓ Detailed Preview by company

Q2FY26 Summary and Top picks

- **Top picks: Staples: Bikaji Foods, Britannia, Nestle, Tata Consumer and HUL; in Discretionary, we also like United Spirits and Asian Paints.**
- **Formal Business Updates: Godrej Consumer, Dabur and Marico in line with our published preview (dated September 29). AWL Agri positively surprised on revenue growth of 24% YoY and volume growth of 5% YoY. Based on Business Updates, minor tweaks have been made to our earlier Q2FY26 preview in this report.**
- **Dabur's Oral Care is likely to report strong performance driven by double-digit growth in Red and Meswak versus likely weak performance by Colgate (we expect 5% YoY sales decline).**
- **Due to GST transition issues; adverse impact on Staples players: volumes/sales are likely to be 2–3%, primarily due to delayed consumer purchases and trade reluctance to stock higher-priced inventory.**
- **Most companies have fully passed on initially GST benefit to consumers. Q2FY26 shall see adverse transition impact on volumes, margins, working capital days. Reversal November onwards.**
- **Inverted duty structures is a challenge. Offset allowed on packaging, any other RM and Services (at 18% GST rate). However, refund is not allowed in case of services (A&P, lease, logistics, outsourced vendor related services) and hence input tax credit may remain unutilised in many companies. Companies eventually are likely to factor this in pricing.**
- **SGST offset mechanism on ultra mega factories/tax holidays, would need modifications, as sales from that factory now generate lower refunds compared with earlier. We forecast companies shall engage with state governments to suitably modify timelines/others.**
- **Heavy rains in Q2FY26 have adversely impacted categories such as carbonated drinks, beverages, beer, ice creams and HI. Varun Beverages, Emami, United Breweries, Dabur, Godrej Consumer shall report an impact. In our view, Tata Consumer RTD is likely to deliver strong performance (we expect volume of 19% YoY). Paints demand was also hurt, but likely to be recouped in coming quarters (deferred rather than lost).**
- **Harsh winter likely in India (Dec'25–Feb'26) due to likely La Niña (> 50% probability). In our view, skin care and immunity products (HUL, Dabur and Emami) likely to see benefit while carbonated drinks and juices (VBL, Dabur) may see demand challenges. Q3FY26 growth for winter portfolios could benefit from last year's mild winter base.**
- **Maharashtra is likely to report double-digit decline in spirits, largely offset by strong growth in Andhra Pradesh and Karnataka.**
- **We estimate ITC's cigarette volumes shall grow 5–6% YoY while Godfrey is likely to grow much faster—likely 20–25% in our view.**
- **GST 2.0 reforms will eventually aid consumption, led by price cuts in larger packs and grammage addition in smaller packs. Rural demand remains resilient, supported by ongoing government schemes and good rains in most parts (except Bihar). In our view, H2FY26 (starting November) is likely to post volume boost for most consumer staples categories.**
- **Government has been supportive: MRP re-stickering voluntary, allowed use of old packaging until March 31, 2026, no longer required to advertise MRP changes. In our view there is flexibility on either grammage increase or price cuts. We do believe odd pricing such as INR4.7 shall go away and GST shall extend life of INR2, INR5, INR10 by four–five years.**
- **Nepal unrest is a slight negative (low single-digit exposure) for companies (operational disruptions, stepping up of plant security, delay in JV projects), normalising now.**
- **Tea prices were down 10–15% YoY in Q2, but may see some increase due to floods in North Bengal (a key monitorable in near term). Coffee (+45% YoY) remains elevated—if prices remain high then good for Tata Consumer's plantations. Copra prices remained range-bound after correcting 10–12% from highs. Palm oil prices are up 4% YoY/8% QoQ; can be slight worry in Q3FY26 (due to lag effect) for food companies.**
- **We reckon our coverage shall clock revenue/volume growth of 6%/2% YoY in Q2FY26 while EBITDA shall remain flat YoY (versus revenue/EBITDA/volume growth of 6%/3%/3% YoY in Q1FY26 and 5%/2%/4% YoY in Q2FY25).**

Q2FY26E performance: Top-tier, mid-tier and laggards

Top-tier : Bikaji Foods, Marico, Tata Consumer, Britannia, Pidilite, United Spirits and CCL Products.

Mid-tier: Nestle, Hindustan Unilever, ITC , Dabur, Asian Paints, Berger Paints, Bajaj Consumer and AWL Agri Business.

Laggards: Emami, Colgate, United Breweries, Varun Beverages, Godrej Consumer and Indigo Paints.

Strong revenue growth: Marico, AWL Agri Business, Bikaji Foods, Tata Consumer, Britannia and CCL Products to be leaders while Emami, Varun Beverages, United Breweries and Colgate to be laggards.

Strong volume growth: Bikaji Foods, Marico, Pidilite and United Spirits to be leaders while Emami, Varun Beverages, United Breweries and Colgate to be laggards.

EBITDA growth: Bikaji Foods (ex-PLI), CCL Products, Asian Paints and Pidilite to be leaders while Emami, AWL Agri Business, United Breweries, Colgate to be laggards.

Decent price hikes: Marico, AWL Agri, Bikaji Foods, Nestle (coffee) and Britannia.

We reckon our coverage shall clock revenue/volume growth of 6%/2% YoY in Q2FY26 while EBITDA shall remain flat YoY (versus revenue/EBITDA/volume growth of 6%/3%/3% YoY in Q1FY26 and 5%/2%/4% YoY in Q2FY25).

Staple companies – Q2FY26 business updates | Key numbers

Marico—Volume and EBITDA in-line: Revenue to surge 30% YoY led by price hike in Parachute; Parachute volume shall decrease in low single-digit. VAHO to expand 18% YoY while International business is likely to rise 23% YoY in CC terms. Saffola franchise is likely to surge 24%. Gross margin pressures are likely to ease H2FY26 onwards.

Dabur – In-line with expectations: We expect revenue growth of 5.4% YoY and EBITDA growth of 5.5% YoY. India volume shall grow 4% YoY (down 7.5% YoY in Q2FY25) aided by strong performance in HPC and Healthcare. Oral care is likely to report a strong performance. Beverage portfolio shall be weak due to heavy rains. International business shall grow 5% YoY.

Godrej Consumer—in line: We forecast revenue growth of 6% YoY and EBITDA decline of 3% YoY due to gross margin pressure and GST transition impact. India business value/volumes to grow 5%/1% YoY. Home Care to grow 8% YoY while Personal Care shall dip 2% YoY due to weak performance in soaps (grammage cuts). Indonesia to decline 2% YoY owing to competitive pricing pressure. GAUM is likely to report double-digit value/volume growth.

AWL Agri business – Better than expectations; volumes bounce back after Q1 dip: We reckon revenue shall surge 24% YoY and volumes shall grow 5% YoY (down -5% in Q1). Edible Oil volume/revenue shall increase 4% YoY/29% YoY. Branded products volume shall grow ~1%. Industry Essentials volume/revenue shall increase 22% YoY/21% YoY on a soft base of -15%/-9%. Food and FMCG reported volumes shall decline 8% YoY/inch up 1% YoY ex-G2G (G2G business discontinued Q4FY25 onwards).

Q2FY26 PREVIEW

SECTOR UPDATE

Selective resilience amid soft season

We reckon the healthcare sector's Q2FY26E EBITDA shall expand ~17% YoY driven by ~18% growth in hospitals and ~12% in diagnostics. The growth is lower than Q1 owing to low seasonal incidences, delayed elective surgeries due to extended monsoons and festivals and high base. Highlights: i) Diagnostics shall report 11–12% organic growth, margin resilient. ii) Hospitals soft, especially APHS, leading to lower occupancy (~560bp lower than Q2FY25). iii) Apollo Pharmacy's growth to sustain at ~17% YoY, while Medplus's growth to improve at ~7%.

We reckon Fortis, Max and Metropolis shall post good numbers, whereas Vijaya and APHS would post softness. Jupiter Life, Dr Lal, Medplus and Laxmi Dental remain on a firm path.

Hospitals: Subdued volume growth; Fortis, Max buck the trend

We forecast hospitals under our coverage shall post steady revenue/EBITDA growth of ~15%/~18% YoY, largely driven by ARPOBs. **APHS:** Hospital revenue growth soft at 8% YoY, but margin to improve to ~25%. Occupancy muted at 67% (versus 73% YoY) with ARPOB up ~16% YoY. Pharmacy growth to sustain at +17% YoY; 24/7 GMV up +8% QoQ, while costs shall stay flat QoQ. **Fortis:** Healthy hospital growth of ~20% YoY and margin healthy at 23% aided by bed additions and Shrimann acquisition. Occupancy is estimated at ~70% and ARPOB growth at ~10% YoY. Agilus is likely to grow at ~8% YoY with margins at ~24% versus 21% in Q2FY25. **Max:** Despite a high dengue base last year, we forecast revenue shall surge ~22% YoY, driven by 10–11% YoY growth from existing hospitals with the balance from four new hospitals. Occupancy at ~77% versus 81% in Q2FY25, albeit on higher beds this year while ARPOB to grow ~3% YoY. EBITDA margins to remain flat YoY at ~26.6%. **Jupiter:** Revenue to grow ~15% YoY led by higher contribution from Pune and Indore. Occupancy to ~67% (versus ~71% in Q2FY25) due to the addition of beds in Indore.

Diagnostics: Mixed bag; soft seasonality hurts growth

We reckon overall diagnostics' revenue/PAT YoY growth shall be 15%/17% led by 11-12% organic growth and rest by acquisitions. Q2FY26E is likely to be soft due to continuous rains, festive season and high base. Metropolis remains one of the fastest growing (+23% YoY reported; +12% YoY organic), followed by Vijaya (~12% YoY) and Dr Lal (~11% YoY), largely driven by volume growth.

Unusually soft Q2; triggers ahead to drive earnings upgrades

While Q2FY26E posted low seasonal incidences. The growth may spill to Q3 and Q4 can benefit from low base effect. Key monitorables: i) Hospitals' commentary on CGHS price hikes. ii) Impact of upcoming bed expansion in FY26 and doctor attrition. iii) Diagnostics – eye on acquisitions, price hikes and DLPL's radiology foray. iv) Medplus –SSSG improvement. v) Laxmi Dental: growth pickup and US tariffs impact.

Q2: Outperformers: Fortis, Max, Metropolis. **Underperformers:** APHS, Vijaya.

Top Picks: Apollo Hospitals, Max Healthcare, Metropolis, Vijaya Diagnostics.

Q2FY26 PREVIEW

SECTOR UPDATE

HV T&D to power ahead

We reckon Nuvama Industrials coverage shall post base OI growth of ~21.7% YoY (ex-BHEL and Siemens) and revenue growth of ~14.5% YoY in Q2FY26E with the consolidated order book rising to ~INR10.7tn on the back of strong awarding in Thermal Gen, Renewables and Power T&D, supported by data centres, EVs and semiconductors.

HV T&D should lead with healthy OIs and execution; however, legacy projects and supply-chain issue delays may weigh on BHEL, Hitachi Energy and TARIL. Non-power private-capex ordering is likely to post another tepid quarter ([exhibits 4–7](#)) and EPC execution to be muted given extended monsoons. Top picks: BHEL, GVTG and Hitachi Energy.

HV T&D momentum strong; private capex patchy; EPC muted

HV T&D—structural upcycle with durable margin resilience: We forecast HV ordering shall remain robust through FY25–28E, driving order book expansion at 30%-plus CAGR. HV margins should sustain above 20% given combined benefits of higher pricing operating leverage and exports for GVTG, CG Power(T&D segment), and other MNC names. Hitachi Energy may continue with lower margins as legacy projects continue until Q3FY26. Our preferred plays—GVTG, Hitachi Energy and CG Power offer a long growth runway ([exhibits 1–2](#)) with peak earnings growth expected till FY28–29 (see [our Industrials update](#)).

Thermal BTG, base-load renewal with steady ordering: CEA has revised thermal capex targets to [97GW by FY35](#) (from 80GW), with scope for further upgrades from replacement of aging thermal assets (~37GW > 35 years by FY32—[exhibit 3](#)), ordering should hold ~10–12GW annually over next few years. BHEL remains our top pick for sustained inflows and an FY27-led turnaround with scope for an 8–10x earnings step-up over FY25–28E as legacy drag fades and new projects enter revenue recognition. However, Q2FY26E results are likely to remain subdued owing to lingering impact of legacy fixed cost projects (Patratu and Ennore).

Non-power private capex to remain soft in near-term: We estimate muted ordering momentum over the next six–nine months with spending largely confined to select high-growth areas such as renewables, data centres and semiconductors while broader industrial capex remains restrained. We remain cautious on ABB, Siemens, Thermax and Honeywell, given tepid private capex growth ([exhibit 4–7](#)) and limited margin visibility. For ABB and Siemens, a more constructive setup hinges on a revival in domestic Railways/Metro tendering and stronger export traction.

Extended monsoons subdue EPC: Prolonged rains constrained site productivity in Q2FY26; hence, we forecast muted growth with margins broadly in line with guidance and see execution improving in H2FY26 for KECI and KPIL. However, L&T may be a bright spot with robust order inflows and overseas execution offsetting weakness in domestic execution. **Sector top picks:** BHEL, GVTG and Hitachi Energy.



Insider Trades & Bulk/Block Deals for the day by Nuvama Alternative & Quantitative Research

Insider Buys:

- No buy trades for the day.

Insider Sells:

- No sell trades for the day.
- Note:** Disclosure made under Reg 13(4), 13(4a) of SEBI (IT) regulations 1992.

Bulk and Block Deals :

Blg Tickers	Date	Company Name	Acquirer/Seller	Buy /Sell	Qty Traded	Price
AIRFLOA	08-Oct-25	AIRFLOA RAIL TECHNOLOGY LIMITED	Ritu Bapna	Buy	179,000	397.18
AFL	08-Oct-25	Abram Food Limited	Ritu Goel	Sell	31,200	134.90
ACTIVEIN	08-Oct-25	Active Infrastructures Limited	Adcc Academy Private Limited	Buy	748,800	186.00
ACTIVEIN	08-Oct-25	Active Infrastructures Limited	Badjate Stock & Shares Pvt Ltd	Sell	623,400	186.00
ACTIVEIN	08-Oct-25	Active Infrastructures Limited	Shilpa Maloo	Sell	90,000	186.00
ADCOUNTY	08-Oct-25	Adcounty Media India Limited	Varsu India Growth Story Scheme 1	Sell	118,400	214.77

ADVANCE	08-Oct-25	Advance Agrolife Limited	Tradebulls Securities Private Limited	Buy	850,713	111.27
ADVANCE	08-Oct-25	Advance Agrolife Limited	Parijata Trading Private Limited	Buy	1,345,000	112.88
ADVANCE	08-Oct-25	Advance Agrolife Limited	Varada Trading Private Limited	Buy	500,000	111.00
ADVANCE	08-Oct-25	Advance Agrolife Limited	Jay Jagannath Steel And Power Limited	Buy	535,000	112.22
ADVANCE	08-Oct-25	Advance Agrolife Limited	Maryada Barter Pvt Ltd	Buy	375,000	108.81
ADVANCE	08-Oct-25	Advance Agrolife Limited	Radiant Computech Private Limited	Buy	1,500,000	114.00
ADVANCE	08-Oct-25	Advance Agrolife Limited	Gyaana Retreat & Services Private Limited	Buy	430,000	114.00
ADVANCE	08-Oct-25	Advance Agrolife Limited	Necta Bloom Vcc - Necta Bloom One	Sell	338,257	114.00
ADVANCE	08-Oct-25	Advance Agrolife Limited	The South Indian Bank Limited	Sell	375,837	114.00
ATH	08-Oct-25	Avance Technologies Ltd	Akarshika Traders Llp	Sell	16,120,002	3.09
ATH	08-Oct-25	Avance Technologies Ltd	Neo Apex Share Broking Services Llp	Sell	10,000,000	3.09
BAGDIGIT	08-Oct-25	B.A.G. Convergence Limited	Model Commercial Pvt Ltd	Buy	120,000	101.00
BAGDIGIT	08-Oct-25	B.A.G. Convergence Limited	Acme Corporate Advisors Private Limited	Buy	222,400	105.82
BAGDIGIT	08-Oct-25	B.A.G. Convergence Limited	Arpna Capital Services Private Limited	Buy	299,200	104.67

BAGDIGIT	08-Oct-25	B.A.G. Convergence Limited	Lovlesh Jain	Buy	200,000	101.00
BAGDIGIT	08-Oct-25	B.A.G. Convergence Limited	Krushnam Nexus Capital Scheme 1	Sell	214,400	101.00
BHAVIK	08-Oct-25	BHAVIK ENTERPRISES LIMITED	Shreni Shares Ltd	Buy	174,000	144.19
BMWVENTL	08-Oct-25	BMW Ventures Limited	Neomile Growth Fund - Series I	Buy	450,000	61.02
BMWVENTL	08-Oct-25	BMW Ventures Limited	Neo Apex Venture Llp	Sell	112,721	60.69
DEEPIN	08-Oct-25	Deep Diamond India Limited	India Fast Forward Advisory Services Private Limited	Sell	828,426	6.30
EEI	08-Oct-25	Eimco Elecon (India) Ltd	Hrti Private Limited	Buy	1,820	2160.48
EEI	08-Oct-25	Eimco Elecon (India) Ltd	Aegis Investment Fund	Buy	100,000	2201.95
EMRL	08-Oct-25	Esha Media Research Limited	Neo Apex Venture Llp	Sell	50,800	49.68
ESFL	08-Oct-25	Essen Speciality Films Limited	Yagnik Bharatkumar Tank	Buy	15,840	243.95
FABTECH	08-Oct-25	Fabtech Technologies Limited	Mansi Share And Stock Broking Private Limited	Sell	252,907	175.43
GUF	08-Oct-25	Globus Constructors & Developers Limited	Al Maha Investment Fund Pcc - Onyx Strategy	Buy	1,578,409	15.15
GUF	08-Oct-25	Globus Constructors & Developers Limited	Elm Park Fund Limited	Sell	1,578,409	15.15
HARSHILA	08-Oct-25	HARSHIL AGROTECH LIMITED	Nirav Dineshbhai Chaudhari	Sell	8,377,204	0.63

INSIDER BULK & BLOCK DEALS

HARSHILA	08-Oct-25	HARSHIL AGROTECH LIMITED	Mandakiniben Pradyumanbhai Patel	Sell	8,000,000	0.63
HARSHILA	08-Oct-25	HARSHIL AGROTECH LIMITED	Neo Apex Venture Llp	Sell	10,000,000	0.63
ISI	08-Oct-25	India Steel Works Ltd	Metal Industrial Pte. Limited	Sell	2,326,436	14.58
INFIBEAM	08-Oct-25	Infibeam Avenues Limited	Samyaktva Construction Llp	Buy	14,913,590	19.12
INFINITY	08-Oct-25	Infinity Infoway Limited	Vpk Global Ventures Fund - Scheme 1	Buy	62,400	294.50
INFINITY	08-Oct-25	Infinity Infoway Limited	Holani Venture Capital Fund- I	Buy	100,000	294.50
INFINITY	08-Oct-25	Infinity Infoway Limited	Benani Capital Scheme 1	Buy	96,000	294.50
INFINITY	08-Oct-25	Infinity Infoway Limited	Aarth. Aif Growth Fund	Buy	81,600	294.50
INFINITY	08-Oct-25	Infinity Infoway Limited	Mansi Share And Stock Broking Private Limited	Buy	32,000	294.83
JFI	08-Oct-25	Jai Corp Ltd	Hrti Private Limited	Buy	65,258	162.22
KVSCASTI	08-Oct-25	KVS Castings Limited	Yuga Stocks And Commodities Private Limited	Buy	100,000	76.74
KVSCASTI	08-Oct-25	KVS Castings Limited	Pashupati Capital Service Pvt Ltd	Sell	200,000	76.74
KANDARP	08-Oct-25	Kandarp Digi Smart BPO Limited	Hemendra Ratilal Mehta	Sell	100,000	98.82
MPKSTEEL	08-Oct-25	M P K STEELS (I) LIMITED	Lrsd Securities Private Limited	Sell	51,200	82.00

Abhilash Pagaria
abhilash.pagaria@nuvama.com

No Code*	08-Oct-25	Manas Polymer N Energie L	Neha Rohan Ramteke	Buy	73,600	143.90
No Code*	08-Oct-25	Manas Polymer N Energie L	Sunrise Investment Opportunities Fund	Sell	99,200	143.73
No Code*	08-Oct-25	Manas Polymer N Energie L	Affluence Gems Privatelimited	Sell	147,200	143.76
MCLR	08-Oct-25	Mcleod Russel India Ltd	Om Pramila Stocks Private Limited	Buy	750,000	54.51
MUNISH	08-Oct-25	Munish Forge Limited	Sandeep Kumar Huf	Buy	138,000	105.00
MUNISH	08-Oct-25	Munish Forge Limited	Nnm Securities Pvt Ltd	Buy	696,000	105.00
MUNISH	08-Oct-25	Munish Forge Limited	Frenzy Commercial Pvt Ltd	Buy	200,400	105.00
MUNISH	08-Oct-25	Munish Forge Limited	Mahalaxmi Brokrage India Private Limited	Buy	294,000	105.00
MUNISH	08-Oct-25	Munish Forge Limited	Pace Stock Broking Services Pvt Ltd	Buy	200,400	105.00
MUNISH	08-Oct-25	Munish Forge Limited	Strategic Sixth Sense Capital Fund	Buy	199,200	105.00
MUNISH	08-Oct-25	Munish Forge Limited	Chaubara Eats Private Limited	Buy	132,000	105.00
MURAE	08-Oct-25	Murae Organisor Limited	Banke Tradelink Private Limited	Sell	29,800,005	0.45
NMPD	08-Oct-25	Narmada Macplast Drip Irrigation Systems Ltd.	Ashik Dhirubhai Sanghvi	Sell	30,000	234.65
NMPD	08-Oct-25	Narmada Macplast Drip Irrigation Systems Ltd.	Rathod Manoj Chhaganlal Huf	Sell	21,000	234.65

Abhilash Pagaria
abhilash.pagaria@nuvama.com

INSIDER BULK & BLOCK DEALS

ORIENTTE	08-Oct-25	Orient Technologies Limited	Hrti Private Limited	Sell	33,416	488.17
	08-Oct-25	Patron Exim Limited	Vijaykumar Jayantilal Thakkar	Buy	1,100,000	9.19
	08-Oct-25	Patron Exim Limited	Manoj Khimchand Raipancholia	Buy	1,136,000	8.85
	08-Oct-25	Patron Exim Limited	Jasmin Purnachandra Mehta	Sell	672,000	8.79
	08-Oct-25	Patron Exim Limited	Nilesh Jobanputra	Sell	1,656,000	8.89
	08-Oct-25	Patron Exim Limited	Niraj Rajnikant Shah	Sell	416,000	9.19
PIGL	08-Oct-25	Power & Instrumentation (Gujarat) Limited	Muskaan Sarin	Sell	116,532	173.87
RBK	08-Oct-25	RBL Bank Limited	Societe Generale	Buy	3,322,631	284.00
RDGAIL	08-Oct-25	RUKMANI DEVI GARG AGRO IMPEX LIMITED	Dnyaneshwar Manohar Shahane	Buy	50,400	75.15
SBCE	08-Oct-25	SBC EXPORTS LIMITED	Pronto Securities Private Limited	Buy	2,640,000	22.40
SPRIGHT	08-Oct-25	SPRIGHT AGRO LIMITED	Neo Apex Venture Llp	Sell	5,882,222	1.03
SZE	08-Oct-25	Salzer Electronics Ltd	Musigma Securities	Sell	3,168	884.94
SHEEL	08-Oct-25	Sheel Biotech Limited	Smp Securities Ltd	Buy	112,000	91.00
SHEEL	08-Oct-25	Sheel Biotech Limited	Shubham Sanjay Damani	Buy	124,000	91.00

Abhilash Pagaria
 abhilash.pagaria@nuvama.com

INSIDER BULK & BLOCK DEALS

SHEEL	08-Oct-25	Sheel Biotech Limited	Preeti Bhauka	Buy	134,000	91.00
SHEEL	08-Oct-25	Sheel Biotech Limited	Craft Emerging Market Fund Pcc- Citadel Capital Fund	Sell	136,000	91.00
SHEEL	08-Oct-25	Sheel Biotech Limited	Mansi Share And Stock Broking Private Limited	Sell	62,000	92.06
SHEEL	08-Oct-25	Sheel Biotech Limited	Longthrive Capital Vcc - Gamma View Funds	Sell	106,000	91.23
SHRINGAR	08-Oct-25	Shringar House of Mangalsutra Limited	Lkp Finance Limited	Buy	67,319	208.24
SHRINGAR	08-Oct-25	Shringar House of Mangalsutra Limited	Nivesh Consultancy Private Limited	Buy	234,067	206.78
SHRINGAR	08-Oct-25	Shringar House of Mangalsutra Limited	Hrti Private Limited	Sell	59,599	207.37
SUCL	08-Oct-25	Sunshine Capital Limited	Neo Apex Venture Llp	Buy	200,000,000	0.32
SUNSKY	08-Oct-25	Sunsy Logistics Limited	Unicorn Fund	Buy	288,000	51.00
SUNSKY	08-Oct-25	Sunsy Logistics Limited	Milan Jayvantlal Mithani(huf)	Buy	150,000	51.00
SUNSKY	08-Oct-25	Sunsy Logistics Limited	Dhirajbhai Vaghjibhai Koradiya	Buy	96,000	51.00
SUNSKY	08-Oct-25	Sunsy Logistics Limited	Kingsman Wealth Management Private Limited	Buy	372,000	51.00
SUNSKY	08-Oct-25	Sunsy Logistics Limited	Hardik Milanbhai Mithani (huf)	Buy	150,000	51.00
SUNSKY	08-Oct-25	Sunsy Logistics Limited	Bhakti Shailesh Nanda	Buy	192,000	51.00

Abhilash Pagaria
abhilash.pagaria@nuvama.com

SUNSKY	08-Oct-25	Sunsky Logistics Limited	Bharatkumar Vasantlal Mandalia Mehta	Buy	150,000	51.00
SUNSKY	08-Oct-25	Sunsky Logistics Limited	Laxmi Goldorna House Limited	Buy	426,000	51.46
SUNSKY	08-Oct-25	Sunsky Logistics Limited	Eastend Infrastructure Private Limited	Buy	93,000	51.00
SUNSKY	08-Oct-25	Sunsky Logistics Limited	Fivex Capital Vcc - Fivex Emerging Star Fund	Buy	576,000	51.00
SUNSKY	08-Oct-25	Sunsky Logistics Limited	Asho Investment And Advisory Private Limited .	Buy	99,000	51.00
SUNSKY	08-Oct-25	Sunsky Logistics Limited	Rikhav Securities Limited	Sell	174,000	51.97
UMIYA	08-Oct-25	Umiya Tubes Limited	Rajeshkumar Amrutlal Akhani	Sell	150,000	26.52
2592901D	08-Oct-25	VASHISHTHA LUXURY FASHION LIMITED	Hemant Jawaharlal Jhaveri	Buy	16,800	173.06
2592901D	08-Oct-25	VASHISHTHA LUXURY FASHION LIMITED	Deepa Hemant Jhaveri	Buy	20,400	178.92
2592901D	08-Oct-25	VASHISHTHA LUXURY FASHION LIMITED	Deepika Murty Malla	Sell	20,400	178.98
VALPAST	08-Oct-25	Valplast Technologies Limited	Jignesh Amrutlal Thobhani	Buy	140,000	57.00
VALPAST	08-Oct-25	Valplast Technologies Limited	Ashu Kumar Aggarwal	Buy	128,000	57.00
VALPAST	08-Oct-25	Valplast Technologies Limited	Ashok Kumar Bardia	Buy	100,000	57.00
VALPAST	08-Oct-25	Valplast Technologies Limited	Sandeep Jain	Buy	200,000	57.00

Abhilash Pagaria
abhilash.pagaria@nuvama.com

INSIDER BULK & BLOCK DEALS

VALPAST	08-Oct-25	Valplast Technologies Limited	Murli Janki & Sons	Buy	100,000	57.00
VALPAST	08-Oct-25	Valplast Technologies Limited	Maheshkumar Sukhlal Jain	Buy	174,000	57.00
ZELIO	08-Oct-25	Zelio E Mobility Limited	Bonanza Portfolio Limited	Buy	200,000	154.90
ZELIO	08-Oct-25	Zelio E Mobility Limited	Sanjay Popatlal Jain	Buy	375,000	154.90
ZELIO	08-Oct-25	Zelio E Mobility Limited	Param Capital	Buy	1,000,000	154.90

Note: Insider Buy/Sell is as defined by SEBI Insider Trading Regulations, 1992 Bulk Deal is defined as any trade in which quantity transacted is more then 0.5% of the companies equity shares listed on the exchanges. The above mentioned data is not completely Extensive as relatively smaller trades have been excluded.

Key Insights

Do use the NIS workbook for a comprehensive analysis | [Workbook <Link>](#)

a) Derivative Positioning | (Px Chg / OI Chg)

- NIFTY Index settled at 25,120 and was down (0.4%) with an OI reduction of (1.4%) indicating marginal Long Unwinding. In the last five days, the benchmark index has seen Long Build Up (2.1% / 5.0%) (Px Chg / OI Chg). The current month futures is trading at a premium of 74 points / 30bps vs premium of 117 points / 47bps a day prior. The current OI value is INR 480bn.
- NSEBANK Index settled at 56,218 and was down (0.4%) with an OI reduction of (3.5%) indicating Long Unwinding. In the last five days, the benchmark index has seen Short Covering (2.9% / (9.7%)) (Px Chg / OI Chg). The current month futures is trading at a premium of 200 points / 36bps vs premium of 229 points / 41bps a day prior. The current OI value is INR 105bn.

a.i) Most Liquid Names (≥ INR 10bn OI Value)

D-o-D	Name	Px Chg (%)	OI Chg (%)	D-o-D	Name	Px Chg (%)	OI Chg (%)
Long Build Up	Pidilite Inds.	1.5	3	Short Covering	RBL Bank	3.9	(8)
	SBI Cards	1.8	3		Titan Company	4.2	(5)
	Tech Mahindra	1.4	2		TCS	1.4	(3)
	Tata Elxsi	2.7	1		Max Healthcare	1.2	(2)
	Infosys	2.6	0		Coforge	1.6	(2)
Short Build Up	I R C T C	(2.2)	5	Long Unwinding	Tata Motors	(2.6)	(3)
	Jindal Steel	(1.6)	4		GAIL (India)	(1.5)	(3)
	Bandhan Bank	(2.7)	3		Eicher Motors	(1.1)	(2)
	Astral	(1.4)	3		Cummins India	(1.5)	(2)
	Bharat Electron	(1.7)	3		Hero Motocorp	(1.8)	(2)

Sorted by highest OI change | >+1% and <-1% Px Chgs are only considered

5 Days	Name	Px Chg (%)	OI Chg (%)	5 Days	Name	Px Chg (%)	OI Chg (%)
Long Build Up	SBI Cards	4.5	23	Short Covering	Hero Motocorp	1.1	(11)
	L&T Fin.Holdings	2.9	19		ICICI Bank	1.9	(10)
	FSN E-Commerce	9.7	16		Kotak Mah. Bank	6.9	(10)
	Aditya Birla Cap	1.5	14		Sun Pharma.Inds.	2.4	(7)
	Astral	2.9	12		One 97	9.8	(5)
Short Build Up	Power Fin.Corp.	(2.2)	20	Long Unwinding	Eicher Motors	(1.3)	(12)
	S A I L	(1.5)	18		SBI Life Insuran	(1.1)	(3)
	Jindal Steel	(3.6)	17		Britannia Inds.	(2.1)	(3)
	Dabur India	(2.0)	11		UltraTech Cem.	(1.2)	(0)
	Cholaman.Inv.&Fn	(1.1)	9				

Sorted by highest OI change | >+1% and <-1% Px Chgs are only considered

Since Exp.	Name	Px Chg (%)	OI Chg (%)	Since Exp.	Name	Px Chg (%)	OI Chg (%)
Long Build Up	SBI Cards	4.5	23	Short Covering	HDFC Bank	3.2	(12)
	L&T Fin.Holdings	2.9	19		Hero Motocorp	1.1	(11)
	FSN E-Commerce	9.7	16		Kotak Mah. Bank	6.9	(10)
	Aditya Birla Cap	1.5	14		Info Edg.(India)	4.9	(5)
	Astral	2.9	12		One 97	9.8	(5)
Short Build Up	Power Fin.Corp.	(2.2)	20	Long Unwinding	Eicher Motors	(1.3)	(12)
	S A I L	(1.5)	18		SBI Life Insuran	(1.1)	(3)
	Jindal Steel	(3.6)	17		Britannia Inds.	(2.1)	(3)
	Dabur India	(2.0)	11		UltraTech Cem.	(1.2)	(0)
	Cholaman.Inv.&Fn	(1.1)	9				

Sorted by highest OI change | >+1% and <-1% Px Chgs are only considered

Abhilash Pagaria
abhilash.pagaria@nuvama.com

Source: Nuvama Alternative & Quantitative Research; Bloomberg; NSE; BSE; Capitaline

e) Price Movers

	Name	CMP	Px Chg (%)		Name	CMP	Px Chg (%)
1D Top Gainers	RBL Bank	286	4.7	1D Top Losers	Kaynes Tech	7,189	(5.3)
	Titan Company	3,566	4.3		UNO Minda	1,311	(4.0)
	Natl. Aluminium	224	3.0		Oberoi Realty	1,578	(3.6)
	IIFL Finance	489	2.9		Titagarh Rail	899	(3.0)
	Hindustan Copper	342	2.9		Aditya Birla Cap	295	(2.7)
	Infosys	1,495	2.5		Mahanagar Gas	1,279	(2.6)
	CESC	166	2.2		H U D C O	226	(2.5)
	TCS	3,027	1.8		JSW Energy	534	(2.5)
	Federal Bank	203	1.7		Dabur India	480	(2.5)
	SBI Cards	920	1.7		Samvardhana MIL	102	(2.4)
Stocks Near 52Wk High	Muthoot Finance	3,263	(0.3)	Stocks Near 52Wk Low	Crompton Gr. Con	286	0.3
	Fortis Health.	1,055	(0.5)		ITC	400	2.5
	Bajaj Finance	1,023	(1.2)		Colgate-Palmoliv	2,218	3.1
	Manappuram Fin.	293	(1.7)		IRB Infra.Devl.	42	3.2
	Indian Bank	761	(1.7)		ACC	1,866	5.1
	H P C L	457	(1.7)		Balkrishna Inds	2,284	6.1
	Hindustan Copper	342	(1.9)		HFCL	73	6.8
	Canara Bank	126	(2.0)		Indian Energy Ex	139	6.9
	Hero Motocorp	5,513	(2.6)		I R C T C	703	7.2
	Maruti Suzuki	16,012	(2.6)		Lupin	1,906	7.4

*For Stocks Near 52Wk High/Low - Px Chg is the % Diff b/w CMP and High/Low

f) Momentum Screener | (Px Chg)

- Price, Volume and % Delivery (Constantly Up For Last 2 Days): NA
- Price, Volume and % Delivery (Constantly Down For Last 2 Days): NA
- 5EMA and 21EMA Fresh Crossover (From Below): NA
- 5EMA and 21EMA Fresh Crossover (From Above): NA
- 50DMA and 200DMA Fresh Crossover (From Below): NA
- 50DMA and 200DMA Fresh Crossover (From Above): NA
- CMP and 200DMA Fresh Crossover (From Below): NA
- CMP and 200DMA Fresh Crossover (From Above): NA

Source: Nuvama Alternative & Quantitative Research; Bloomberg; NSE; BSE; Capitaline

DISCLAIMER

Nuvama Wealth Management Limited (defined as “NWML” or “Research Entity”) a company duly incorporated under the Companies Act, 1956 (CIN No L67110MH1993PLC344634) having its Registered office situated at 801- 804, Wing A, Building No. 3, Inspire BKC, G Block, Bandra Kurla Complex, Bandra East, Mumbai – 400 051 is regulated by the Securities and Exchange Board of India (“SEBI”) and is licensed to carry on the business of broking, Investment Adviser, Research Analyst and other related activities. Name of Compliance/Grievance officer: Mr. Atul Bapna, E-mail address: complianceofficer.nwm@nuvama.com Contact details +91 (22) 6623 3478 Investor Grievance e-mail address- grievance.nwm@nuvama.com

This Report has been prepared by NWML in the capacity of a Research Analyst having SEBI Registration No.INH000011316 and Enlistment no. 5723 with BSE and distributed as per SEBI (Research Analysts) Regulations 2014. This report does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Securities as defined in clause (h) of section 2 of the Securities Contracts (Regulation) Act, 1956 includes Financial Instruments and Currency Derivatives. The information contained herein is from publicly available data or other sources believed to be reliable. This report is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in Securities referred to in this document (including the merits and risks involved), and should consult his own advisors to determine the merits and risks of such investment. The investment discussed or views expressed may not be suitable for all investors.

This information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject NWML and associates, subsidiaries / group companies to any registration or licensing requirements within such jurisdiction. The distribution of this report in certain jurisdictions may be restricted by law, and persons in whose possession this report comes, should observe, any such restrictions. The information given in this report is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This information is subject to change without any prior notice. NWML reserves the right to make modifications and alterations to this statement as may be required from time to time. NWML or any of its associates / group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. NWML is committed to providing independent and transparent recommendation to its clients. Neither NWML nor any of its associates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including loss of revenue or lost profits that may arise from or in connection with the use of the information. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. Past performance is not necessarily a guide to future performance. The disclosures of interest statements incorporated in this report are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. The information provided in these reports remains, unless otherwise stated, the copyright of NWML. All layout, design, original artwork, concepts and other Intellectual Properties, remains the property and copyright of NWML and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the copyright holders.

NWML shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, break down of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of the NWML to present the data. In no event shall NWML be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the NWML through this report.

We offer our research services to clients as well as our prospects. Though this report is disseminated to all the customers simultaneously, not all customers may receive this report at the same time. We will not treat recipients as customers by virtue of their receiving this report.

NWML and its associates, officer, directors, and employees, research analyst (including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the Securities, mentioned herein or (b) be engaged in any other transaction involving such Securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company(ies) discussed herein or act as advisor or lender/borrower to such company(ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance. (c) NWML may have proprietary long/short position in the above mentioned scrip(s) and therefore should be considered as interested. (d) The views provided herein are general in nature and do not consider risk appetite or investment objective of any particular investor; readers are requested to take independent professional advice before investing. This should not be construed as invitation or solicitation to do business with NWML (e) Registration granted by SEBI and certification from NISM in no way guarantee performance of NWML or provide any assurance of returns to investors and clients.

NWML or its associates may have received compensation from the subject company in the past 12 months. NWML or its associates may have managed or co-managed public offering of securities for the subject company in the past 12 months. NWML or its associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. NWML or its associates may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. NWML or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Research analyst or his/her relative or NWML's associates may have financial interest in the subject company. NWML and/or its Group Companies, their Directors, affiliates and/or employees may have interests/ positions, financial or otherwise in the Securities/Currencies and other investment products mentioned in this report. NWML, its associates, research analyst and his/her relative may have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (i) exchange rates can be volatile and are subject to large fluctuations; (ii) the value of currencies may be affected by numerous market factors, including world and national economic, political and regulatory events, events in equity and debt markets and changes in interest rates; and (iii) currencies may be subject to devaluation or government imposed exchange controls which could affect the value of the currency. Investors in securities such as ADRs and Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Research analyst has served as an officer, director or employee of subject Company: No

NWML has financial interest in the subject companies: No

NWML's Associates may have actual / beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report.

Research analyst or his/her relative has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No

NWML has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No

Subject company may have been client during twelve months preceding the date of distribution of the research report.

There were no instances of non-compliance by NWML on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years. A graph of daily closing prices of the securities is also available at www.nseindia.com

Analyst Certification:

The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Additional Disclaimers**Disclaimer for U.S. Persons**

This research report is a product of NWML, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by NWML only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a-6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, NWML has entered into an agreement with a U.S. registered broker-dealer, Nuvama Financial Services Inc. (formerly Edelweiss Financial Services Inc.) ("NFSI"). Transactions in securities discussed in this research report should be effected through NFSI.

Disclaimer for U.K. Persons

The contents of this research report have not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 ("FSMA").

In the United Kingdom, this research report is being distributed only to and is directed only at (a) persons who have professional experience in matters relating to investments falling within Article 19(5) of the FSMA (Financial Promotion) Order 2005 (the "Order"); (b) persons falling within Article 49(2)(a) to (d) of the Order (including high net worth companies and unincorporated associations); and (c) any other persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as "relevant persons").

This research report must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this research report relates is available only to relevant persons and will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this research report or any of its contents. This research report must not be distributed, published, reproduced or disclosed (in whole or in part) by recipients to any other person.

Disclaimer for Canadian Persons

This research report is a product of NWML, which is the employer of the research analysts who have prepared the research report. The research analysts preparing the research report are resident outside the Canada and are not associated persons of any Canadian registered adviser and/or dealer and, therefore, the analysts are not subject to supervision by a Canadian registered adviser and/or dealer, and are not required to satisfy the regulatory licensing requirements of the Ontario Securities Commission, other Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and are not required to otherwise comply with Canadian rules or regulations regarding, among other things, the research analysts' business or relationship with a subject company or trading of securities by a research analyst.

This report is intended for distribution by NWML only to "Permitted Clients" (as defined in National Instrument 31-103 ("NI 31-103")) who are resident in the Province of Ontario, Canada (an "Ontario Permitted Client"). If the recipient of this report is not an Ontario Permitted Client, as specified above, then the recipient should not act upon this report and should return the report to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any Canadian person.

NWML is relying on an exemption from the adviser and/or dealer registration requirements under NI 31-103 available to certain international advisers and/or dealers. Please be advised that (i) NWML is not registered in the Province of Ontario to trade in securities nor is it registered in the Province of Ontario to provide advice with respect to securities; (ii) NWML's head office or principal place of business is located in India; (iii) all or substantially all of NWML's assets may be situated outside of Canada; (iv) there may be difficulty enforcing legal rights against NWML because of the above; and (v) the name and address of the NWML's agent for service of process in the Province of Ontario is: Bamac Services Inc., 181 Bay Street, Suite 2100, Toronto, Ontario M5J 2T3 Canada.

Disclaimer for Singapore Persons

In Singapore, this report is being distributed by Nuvama Investment Advisors Private Limited (NIAPL) (Previously Edelweiss Investment Advisors Private Limited ("EIAPL")) (Co. Reg. No. 201016306H) which is a holder of a capital markets services license and an exempt financial adviser in Singapore and (ii) solely to persons who qualify as "institutional investors" or "accredited investors" as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Pursuant to regulations 33, 34, 35 and 36 of the Financial Advisers Regulations ("FAR"), sections 25, 27 and 36 of the Financial Advisers Act, Chapter 110 of Singapore shall not apply to NIAPL when providing any financial advisory services to an accredited investor (as defined in regulation 36 of the FAR. Persons in Singapore should contact NIAPL in respect of any matter arising from, or in connection with this publication/communication. This report is not suitable for private investors.

Disclaimer for Hong Kong persons

This report is distributed in Hong Kong by Nuvama Investment Advisors (Hong Kong) Private Limited (NIAHK) (Previously Edelweiss Securities (Hong Kong) Private Limited (ESHK)), a licensed corporation (BOM -874) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to Section 116(1) of the Securities and Futures Ordinance "SFO". This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The report also does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of any individual recipients. The Indian Analyst(s) who compile this report is/are not located in Hong Kong and is/are not licensed to carry on regulated activities in Hong Kong and does not / do not hold themselves out as being able to do so.

INVESTMENT IN SECURITIES MARKET ARE SUBJECT TO MARKET RISKS. READ ALL THE RELATED DOCUMENTS CAREFULLY BEFORE INVESTING.

Abneesh Roy

Head of Research Committee

Abneesh.Roy@nuvama.com
